Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A comprehensive profile of recurrent glioblastoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The focal adhesion-associated proteins DOCK5 and GIT2 comprise a rheostat in control of epithelial invasion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prdm5 suppresses Apc(Min)-driven intestinal adenomas and regulates monoacylglycerol lipase expression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Actively personalized vaccination trial for newly diagnosed glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Extracranial metastases in glioblastoma-Two case stories

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

In spite of relentless efforts to devise new treatment strategies, primary glioblastomas invariably recur as aggressive, therapy-resistant relapses and patients rapidly succumb to these tumors. Many therapeutic agents are first tested in clinical trials involving recurrent glioblastomas. Remarkably, however, fundamental knowledge on the biology of recurrent glioblastoma is just slowly emerging. Here, we review current knowledge on recurrent glioblastoma and ask whether and how therapies change intra-tumor heterogeneity, molecular traits and growth pattern of glioblastoma, and to which extent this information can be exploited for therapeutic decision-making. We conclude that the ability to characterize and predict therapy-induced changes in recurrent glioblastoma will determine, whether, one day, glioblastoma can be contained in a state of chronic disease.

OriginalsprogEngelsk
TidsskriftOncogene
Vol/bind35
Udgave nummer45
Sider (fra-til)5819-5825
Antal sider7
ISSN0950-9232
DOI
StatusUdgivet - 10 nov. 2016

ID: 49459696